Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

COVID-19’s Damage To Gene Therapy Development May Last Years

Jun 15 2021

• By Derrick Gingery

Peter Marks at FDLI Regenerative Medicine conference screenshot — CBER Director Peter Marks said the pandemic also exasperated the backlog of pending INTERACT meetings. • Source: screenshot

Related Content

PDUFA VII Negotiations Completed, Commitment Letter Ratification Ongoing

Mar 22 2021

CBER Proposes Increasing Cell, Gene Therapy Staff In PDUFA VII

Jan 07 2021

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Dec 01 2020

US FDA’s Gene Therapy Work Feeling The Effects Of Pandemic Response

Jun 10 2020

Patient-Reported Data In COVID-Impacted Trials: US FDA Cautions Against Missing Data, Potential Bias

Jun 07 2020

Scientific Wave Pushes CBER Into Brighter Light

Mar 26 2020

Additional Topics

United States Regenerative Medicine Regulation Review Pathway BioPharmaceutical

More from Cell & Gene Therapies

More from Advanced Technologies

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window